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Abstract
Objective: In a hospital based setting, identify factors which inﬂ  uence the cost of colorectal cancer care?
Design: Retrospective case note review
Setting: Nottingham, United Kingdom
Participants: 227 patients treated for colorectal cancer
Methods: Retrospective review of the hospital records provided the primary data for the costing study and included all 
CRC related resource consumption over the study period.
Results: Of 700 people identiﬁ  ed, 227 (32%) sets of hospital notes were reviewed. The median age of the study group was 
70.3 (IQR 11.3) years and there were 128 (56%) males. At two years, there was a signiﬁ  cant difference in costs between 
Dukes D cancers (£3641) and the other stages (£3776 Dukes A; £4921 Dukes B). Using univariate and multivariate regression, 
the year of diagnosis, Dukes stage of disease, intensive nursing care, stoma requirements and recurrent disease all signiﬁ  cantly 
affected the total cost of care.
Conclusions: CRC remains costly with no signiﬁ  cant difference in costs if diagnosed before compared to after 1992. Very 
early and very late stage cancers remain the least costly stage of cancers to treat. Other signiﬁ  cant effectors of hospital costs 
were the site of cancer (rectal), intensive nursing care, recurrent disease and the need for a stoma.
Keywords: colorectal cancer, cost, hospital, Dukes stage, screening
Introduction
Colorectal cancer (CRC) care is costly partly because it is common (16000 deaths per year) and involves 
expensive, specialist hospital based operative intervention. In addition, its natural history of recurrence 
has prompted long periods in follow up programmes with additional operative intervention or palliative 
care for those with detected recurrences. This cost is set to rise further with the introduction of popula-
tion based screening for CRC last year for 60 year olds in England, at a cost of £37.5 million in the ﬁ  rst 
two years alone.
1
Although costing for CRC is therefore important, there remains considerable variation in costing esti-
mates, even if subdivided by stage of disease (Appendix 1).
2–9 In addition, management of this disease 
has changed in many areas, with shorter hospital stays, increasing use and range of adjuvant therapies and 
calls for more intensive follow up.
10,11 Whynes et al. examined the costs of hospital based care, publishing 
their ﬁ  ndings in the BJC in 1993.
3 We undertook a similar costing exercise to examine whether hospital 
costs have altered signiﬁ  cantly, whether very early and very late stage cancers remain the least costly, and 
to consider the implications for changes in future management such as population based screening.
Methods
Study population
Following Trust Research and Development approval, people with histologically proven CRC diagnosed 
between February 1981 and August 2002 were identiﬁ  ed from computerised pathology records of the 28
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audit department at Queen’s Medical Centre, 
Nottingham. 700 cases of CRC were identiﬁ  ed. 
The list was ordered chronologically and every 
third set of notes was selected, with 227 cases 
being reviewed. Retrospective review of the 
hospital records provided the primary data for the 
costing study and included all CRC related 
resource consumption over the study period (e.g. 
initial assessment, operative intervention and 
outpatient follow up) (Appendix 2). Consumed 
resources related to research projects or commu-
nity based activities (e.g. palliative care) were 
excluded. As the initial admission for treatment 
can underestimate the total hospital based costs, 
the costing period was deﬁ  ned as the time from 
primary operation or diagnosis to death, discharge 
from hospital based follow up or the study end 
date (01/09/2002). Many factors were analysed, 
with year of diagnosis being grouped as either pre 
or post 01/01/1992.
Costs
A pragmatic approach to costing was taken using 
existing market costs rather than calculating oppor-
tunity cost. The year of operation was considered 
the base year (Year 0) with costs from later calendar 
years being discounted at 3%. Costs were in pounds 
sterling (£) and a treatment level perspective was 
taken for the analysis. The direct hospital costs, 
listed in Appendix 3, were obtained from three 
sources: the hospital ﬁ  nance department (personal 
communication Ms O’Connor), 2001 NHS refer-
ence costs
12 and the Nottingham City Hospital 
pharmacy. Costs were extrapolated to 2001 costs, 
using the Gross Domestic Product deﬂ  ator.
13
Statistical analysis
The basic demographics were described in terms of 
median values and their accompanying interquartile 
ranges (IQR), with non-parametric tests being used 
where appropriate (Chi square test for proportions, 
Kruskal Wallis H test) as the cost data was not 
normally distributed. Following loge transformation 
of total and follow up costs, univariate and multi-
variate linear regression analysis was performed. 
The multivariate regression included all possible 
explanatory variables in the model as categorical 
variables with exponentiated coefficients and 
conﬁ  dence intervals being used to calculate the 
geometric mean ratios. Statistical analysis was 
performed in SPSS 11.0 (SPSS Inc, Chicago) and 
Stata 7.0 (Stata Corporation, Texas).
Results
Of 700 people identiﬁ  ed, 227 (32%) sets of hospital 
notes were reviewed. Table 1 presents the basic 
demographics of the study group, by Dukes stage of 
disease. The median age of the study group was 70.3 
(IQR 11.3) years and there were 128 (56%) males. 
The majority of cases were elective admissions (75%) 
although the proportion of emergency cases increased 
with advancing stage. At the study end date, 78 (34%) 
were still alive. More left sided cancers were resected 
in the early stages of disease and proportionally more 
stomas were formed in those with advanced disease. 
In 12 cases, the site of the tumour and its correspond-
ing Dukes stage were unknown.
Patients with Dukes A cancers spent the least 
number of days in hospital, made up the highest 
proportion of the alive group and 45% (n = 14) had 
been discharged from follow up by the study end 
date. Their median age at diagnosis was 68.3 
(IQR 11.0) years and their median time from opera-
tion to death or discharge was 7.7 (IQR 7.5) years, 
compared to 1.2 years (IQR 7.5) for Dukes D 
cancers.
Table 2 presents the two year and total cost by 
various demographic, disease and treatment char-
acteristics that were considered. Across the whole 
group, the median two year cost was £4479 (IQR 
4155) and the total cost was £5376 (IQR 5312). 
Within the ﬁ  rst two years, there was no difference 
in cost by gender but overall, males cost £1186 
more than females and survived one month longer. 
Subjects under 70 years of age survived 1.9 years 
longer than those over 70 although there was no 
statistically signiﬁ  cant cost difference.
Known sites cost on average £3000 more than 
unknown sites (at two years) but the survival dif-
ference was marked (up to 6.5 years). Overall, 
rectal cancers cost £2793 more than a right sided 
cancer (caecum to splenic ﬂ  exure) and the marked 
increase in costs related to intensive nursing care 
requirements were statistically signiﬁ  cant at both 
the two year stage (£2350 p  0.01) and overall. 
This is despite those patients having a marked 
shortening of their life expectancy (3.9 years). The 
requirement of a stoma also saw a statistically 
signiﬁ  cant increase in cost over the two year and 
total period of follow up (p  0.01). Recurrent 
disease was a predictor of increased costs, with a 29
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statistically signiﬁ  cant increase in costs at two 
years (p = 0.01) and overall (p  0.05).
Considering disease stage, unknown cancers 
cost the least (p  0.01) and spent the least time 
in follow up. However, even when unknown 
cancers were excluded, a signiﬁ  cant difference in 
two year costs was detected between Dukes D 
cancers (£3641) and the other stages (range £3776 
Dukes A to £4921 Dukes B). This signiﬁ  cance did 
not persist for total costs probably due to widening 
interquartile ranges.
When undertaking univariate analysis, the 
occurrence of rectal cancer, the need for a stoma, 
recurrent disease, or a Dukes B or C cancer 
predicted a signiﬁ  cant difference in costs (Table 3). 
When all possible explanatory variables were 
submitted to multivariate regression, Dukes A to C, 
intensive nursing care, stoma requirements and 
recurrent disease all reached signiﬁ  cance.
In order to take account of the wide variation 
in follow up periods, Table 4 considers the total 
cost per month by Dukes stage and various char-
acteristics. Dukes C and particularly Dukes D 
cancers cost signiﬁ  cantly more per month, with the 
significance becoming more prominent when 
unknown cancer stage was excluded. Late stage 
cancers cost £110 per month more but survived 
2.5 years less than earlier stage cancers while the 
inﬂ  uence of intensive nursing care, recurrence or 
stoma costs on costs persisted. With multivariate 
regression, Dukes stage A and C, intensive nursing 
care, recurrent disease and year of diagnosis 
predicted a signiﬁ  cant difference in costs.
Discussion
Findings
CRC remains costly with no signiﬁ  cant difference 
in costs if diagnosed before compared to after 1992. 
Very early and very late stage cancers remain the 
least costly stage of cancers to treat. Other 
signiﬁ  cant affectors of hospital costs were the site 
of cancer (rectal), intensive nursing care, recurrent 
disease and the need for a stoma.
Strengths and limitations
The method, dataset and data capture
The decision to limit the study to around 200 sets 
of notes was considered a compromise between an 
adequate sample size and the limitations of time 
and costs. Ordering the dataset by hospital number 
and sampling every third set of notes was consid-
ered an appropriate randomisation method. Choos-
ing the work of only one institution may limit the 
generalisability of results although there was no 
evidence that the clinical management in QMC 
differed from other U.K. centres. Hospital Episodes 
Statistics (HES) were not used as they were not a 
recognised research tool for the time period of the 
study (i.e. 1981 onwards) and they have no indi-
vidual level data, so detailed costing techniques 
would have been sacriﬁ  ced for the larger sample 
size.
14,15 An initial inspection of the full data set 
would have been useful to look for trends in disease 
stage and other factors over time; however, this 
would have required a review of every set of notes 
which was not feasible in the time period.
What is recorded in hospital records is deter-
mined not by the needs of research but by what is 
felt relevant to direct patient care so the quality of 
this recording for research purposes was variable 
and sometimes incomplete. The cost of chemo-
therapeutic agents may have been underestimated 
as the majority of regimens included in this study 
were administered within trial settings under 
oncologists. Improved cost data is becoming avail-
able, looking at both adjuvant and palliative che-
motherapy and also oral versus intravenous 
administration.
16
Appropriate end points for costs
Following all patients until their death would have 
provided a more complete picture of the hospital 
based costs as death is a useful economic end point, 
where one can be certain of no further costs being 
incurred. However, in the study 66% of subjects 
had died by the end date of the study, with a further 
proportion (mainly Dukes A and B cancers) dis-
charged from further hospital based follow up. The 
proportion of Dukes A cancers were small but cor-
responded with national ﬁ  gures, which found small 
proportions of very early or very late stage cancers 
(60.3% Dukes B or C; 15.4% unknown stage).
17
Costs by stage of cancer 
and various characteristics
The inclusion of the twelve cases of unknown stage 
(which were all likely to be Dukes D cancers) 
proved to have a considerable effect on the results 
despite their short survival. Their stage was 32
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unknown because they either underwent palliative 
surgery (e.g. colostomy rather than tumour 
resection) or medical palliative care and none 
received intensive nursing care, palliative chemo-
therapy or any follow up. The main tables and 
multivariate analyses present data with unknown 
stage excluded but further analysis is presented 
beneath them, with all patients included. As they 
survived such a short period of time their costs are 
unsurprisingly very small.
Considering the remaining four Dukes stages, 
Dukes D cancers appeared to consistently incur 
the least hospital based costs. Of those with Dukes D 
cancer, 71% had a palliative or diagnostic operation 
with a similar post-operative stay to intermediate 
stage cancers. Although the lower costs could be 
partly related to less radical operative intervention, 
the most likely reason for the reduced costs is the 
short survival period post discharge. Outpatient 
costs were on average £1067 less than follow up 
of a Dukes A cancer.
Considering the European publications, the 
results are fairly similar to previous prospective 
studies by Whynes in 1993, although considerably 
less than the ﬁ  gures used for the economic modelling 
of the U.K. national screening trial (Appendix 1).
3,9 
With a statistically signiﬁ  cant difference in costs 
between different stages of disease, it raises con-
cerns over the use of a single NHS reference cost 
for operations on any cancer stage, as seen in the 
costing paper on ﬂ  exible sigmoidoscopy screening 
in the U.K. Charitable donations are another reason 
for cost disparity as in the U.K. currently, most 
palliative care facilities require considerable chari-
table donations on top of limited direct NHS funds. 
The NHS cancer plan has budgeted for hospices 
and other facilities, so the economics in this area 
are likely to change considerably.
18
Table 3. Univariate analysis and multivariate regression of total costs in all patients.
Dependent variable Ratio of geometric mean (95% conﬁ  dence interval)
Univariate Signiﬁ  cance (p) Multivariate** Signiﬁ  cance (p)
Stage of cancer
  Dukes A 1.2 (0.9–1.6) 0.27 1.5 (1.1–2.0) 0.05
  Dukes B 1.4 (1.0–1.8) 0.05 1.8 (1.4–2.4) 0.01
  Dukes C 1.4 (1.1–1.8) 0.05 1.5 (1.2–2.0) 0.01
 Dukes  D* 1 – 1
Male 1.2 (1.0–1.4) 0.05 1.1 (0.9–1.3) 0.28
Female* 1 1
Site of cancer
 Rectum 1.3  (1.1–1.6) 0.05 1.1 (0.9–1.4) 0.29
  Left sided 1.1 (0.9–1.4) 0.47 1.0 (0.8–1.3) 0.91
 Right  sided* 1 1
Standard nursing care 0.7 (0.5–1.0) 0.06 0.7 (0.5–0.9) 0.05
Intensive nursing care* 1 1
No stoma 0.8 (0.6–0.9) 0.01 0.8 (0.6–0.9) 0.01
Stoma formed* 1 1
No recurrence* 1 1
Recurrence 1.3 (1.1–1.5) 0.01 1.5 (1.2–1.8) 0.01
Pre 1992 1.1 (1.0–1.4) 0.13 1.2 (1.0–1.4) 0.05
1992 onwards* 1 1
*Baseline category. Signﬁ  cance (p)—0.05 level.
**Customised multivariate linear regression.
If unknown stage of cancer included in univariate analysis, ratio of geometric means were Dukes A 4.5 (p  0.01); Dukes B 5.1 (p  0.01); 
Dukes C 5.2 (p  0.01); Dukes D 3.8 (p  0.01) If unknown stage of cancer included in multivariate regression, ratio of geometric means 
were Dukes A 2.2 (p  0.05); Dukes B 2.7 (p  0.01); Dukes C 2.3 (p  0.05); Dukes D 1.5 (p = 0.24).33
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Studies from Medicare patients in the United 
States found costs were four times higher for more 
advanced disease than for early stages yet the 
mean total cost of palliative care in the U.K. for 
any cancer was estimated to be only £2828 
(1999).
19,20 One of the main difﬁ  culties with U.S. 
economic data is that it is based on market costs 
and so rarely reﬂ  ects the true cost of providing a 
service.
Despite a lower risk of recurrence, more was 
spent on outpatient visits and investigations for 
Dukes A cancers than for either Dukes B or C 
cancers. Considering areas for potential cost 
saving, targeted follow up of very early cancers 
could be one area for consideration.
21
Rectal cancers appeared to be the most costly 
site of cancer, possibly due to an increased risk of 
local recurrence or the need for a stoma (temporary 
or permanent).
There is currently little published work on the 
daily resource use of stoma patients despite stoma 
care products being essential, costly and commonly 
prescribed. The high daily resource use (two bags 
per day plus condiments) and the cost of each bag 
(£2.2) probably explains why having a stoma 
effected overall costs so signiﬁ  cantly, particularly 
if the stoma was permanent. Further costs were 
incurred due to operations for the complications 
or reversal of such stomas.
Implications
Population based screening in England raises 
additional CRC cost issues. Previous studies have 
suggested that signiﬁ  cant cost savings should not 
be expected from population screening initially 
despite the increased number of early cancers 
detected.
22 Setting up such a programme is costly 
Table 4. Total cost per month in all cases, by Dukes stage and various characteristics.
Characteristics Number n (%) Median cost per month 
post diagnosis £ (IQR)
p value Median time in follow up 
program years (IQR)
Stage of cancer
  Dukes A 31 (14) 69 (105) 7.7 (7.5)
  Dukes B 76 (34) 104 (299) 6.2 (7.9)
  Dukes C 77 (34) 151 (426) 4.9 (6.9)
  Dukes D 31 (14) 370 (1197) 1.2 (7.4)
 Unknown 12  (5) 81 (−) p  0.01* 0 (0.6)
Male 128 (56) 112 (367) 5.4 (10.7)
Female 99 (44) 116 (317) p = 0.82 4.4 (7.4)
Site of cancer
  Rectum 92 (41) 94 (321) 6.5 (11.0)
  Left sided 67 (30) 118 (253) 5.9 (7.8)
  Right sided 60 (26) 196 (528) 2.2 (7.1)
 Unknown** 8  (4) 0 p = 0.18 0 (0.6)
Standard nursing care 214 (94) 104 (327) 5.4 (8.4)
Intensive nursing care 13 (6) 428 (9580) p  0.01 1.5 (6.8)
No stoma 157 (69) 91 (333) 5.1 (8.4)
Stoma formed 70 (31) 205 (428) p  0.05 5.4 (6.9)
No recurrence 103 (45) 75 (146) 7.3(11.2)
Recurrence 124 (55) 256 (506) p  0.01 2.4 (5.6)
Pre 1992 74 (33) 46 (91) 13.1 (10.8)
1992 onwards 153 (67) 174 (437) p  0.01 2.7 (6.1)
Costs in Pounds Sterling (2001), discounted at 3% rate. Median costs (Interquartile range).
*When unknown stage included, p  0.05; when excluded p  0.01.
**Unknown site excluded as costs per month negligible and rejected by SPSS.34
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before any subject is actually screened and it is 
important that health planners have ensured that 
resources are available both in terms of investiga-
tions (e.g. endoscopy, radiology) and colorectal 
services (e.g. medical and nursing staff).
Further developments of chemotherapeutic 
agents and completion of the trials proving their 
clinical effectiveness may intensify the manage-
ment of advanced stage disease. A recent study 
estimated palliative chemotherapy to cost between 
£2576 and £5051, depending on the therapy used.
23 
The use of oral chemotherapeutic agents may 
reduce the inpatient costs of such treatments but 
we may ultimately see a similar trend to hospital 
costs as in the U.S, with advanced stage disease 
costing as much or more than early, curable disease 
despite shorter survival periods.
Payment by results and the use of National Tar-
iffs has meant that hospitals receive a set cost from 
primary care trusts for certain operative procedures 
(National Tariffs) irrespective of how costly it is to 
provide the service.
24 Whether this will encourage 
individual trusts to analyse their costs more closely 
(and so improve health economic data in this area) 
is unclear. NHS reference costs remain the most 
widely used and accepted data in the NHS to date.
Hospital based colorectal cancer care is costly. 
Population screening, laparoscopic colorectal sur-
gery, intensive follow up and polyp surveillance, 
new chemotherapeutic agents and more aggressive 
surgery for metastatic disease are likely to see these 
costs rise further. This may well be partially offset 
by the identiﬁ  cation of early stage polyps and can-
cers, fewer stomas, less need for intensive care (less 
invasive laparoscopic surgery), targeted follow up 
programmes and shorter hospital stays but indi-
vidual trusts may have to scrutinise their costs more 
closely if the National Tariffs do not adequately 
reward them for the care provided. Overall, all the 
above should hopefully see a fall in CRC mortality 
and better patient care despite the costs.
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Appendix 2. Information extracted from the hospital records.
Section 1: Patient demographics
Section 2: Initial operation and post operative care
Pre-operative investigations
Operation type and post operative management and morbidity
Histopathological results—Dukes stage of disease
Section 3: Hospital based follow up
Timing and indication for outpatient appointment
Clinic, endoscopy and radiology based investigations (e.g. Ultrasound, Colonoscopy)
Section 4: Adjuvant therapy and stoma care
Type of adjuvant therapy and associated morbidity
Type of stoma
Section 5: Further operations (e.g. recurrent disease, metachronous lesions)
As for initial operation
Section 6: Medical comorbidity and mortality
Medical comorbidity (e.g. Myocardial infarction)
Cause and date of death (post mortem ﬁ  ndings if available)
Appendix 3. Various “direct” hospital costs and their origin.
Setting Hospital resource Cost (£) pounds sterling HRG code*
Inpatient
  Operation Major operation £2,494 F34
Minor operation (e.g. reversal of stoma) £780 F44
  Post operative care Adult intensive care unit £1263/day QMC+
Surgical High dependency unit £99 1/day QMC+
Surgical ward £370/day QMC+
Outpatient
  Surgical clinic New patient appointment £93 QMC+
Follow up appointment £47 QMC+
Endoscopy Flexible sigmoidoscopy £119 F14op
Colonoscopy £127 F06op
Radiology Chest X ray £71 F20op
Ultrasound of liver £91 F18op
Double contrast barium enema £120 F15op
CT abdomen/pelvis £143 F04op
MRI pelvis £188 F03op
Adjuvant therapy Pre or post operative radiotherapy £500 NCH*
Chemotherapy £709–8322 NCH*
HRG code—NHS reference costs 2001.
Queens Medical Centre QMC+ submissions for NHS reference costs Chemotherapy costs NCH* from Nottingham City Hospital Pharmacy 
depended on the treatment regimen (Quasar 5/7 trial £709 to Irinotecan/5FU/FA £8322).